HUE047822T2 - Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok - Google Patents
Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékokInfo
- Publication number
- HUE047822T2 HUE047822T2 HUE16714019A HUE16714019A HUE047822T2 HU E047822 T2 HUE047822 T2 HU E047822T2 HU E16714019 A HUE16714019 A HU E16714019A HU E16714019 A HUE16714019 A HU E16714019A HU E047822 T2 HUE047822 T2 HU E047822T2
- Authority
- HU
- Hungary
- Prior art keywords
- morpholin
- pyrazole
- immune
- cancer
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL411864A PL236355B1 (pl) | 2015-04-02 | 2015-04-02 | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE047822T2 true HUE047822T2 (hu) | 2020-05-28 |
Family
ID=55650626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16714019A HUE047822T2 (hu) | 2015-04-02 | 2016-03-30 | Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10138247B2 (hu) |
| EP (1) | EP3277687B1 (hu) |
| JP (1) | JP6665201B2 (hu) |
| KR (1) | KR102559190B1 (hu) |
| CN (1) | CN107743489B (hu) |
| AU (1) | AU2016241568B2 (hu) |
| BR (1) | BR112017020131B1 (hu) |
| CA (1) | CA2978828A1 (hu) |
| DK (1) | DK3277687T3 (hu) |
| EA (1) | EA032826B1 (hu) |
| ES (1) | ES2765642T3 (hu) |
| HR (1) | HRP20192195T1 (hu) |
| HU (1) | HUE047822T2 (hu) |
| MX (1) | MX2017011423A (hu) |
| PL (2) | PL236355B1 (hu) |
| PT (1) | PT3277687T (hu) |
| SI (1) | SI3277687T1 (hu) |
| WO (1) | WO2016157091A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022064458A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| CN114957261B (zh) * | 2022-05-17 | 2023-06-23 | 重庆文理学院 | 一种具有抗头颈癌作用的化合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9900575A3 (en) * | 1996-02-07 | 2001-11-28 | Neurocrine Biosciences Inc San | Pyrazolopyrimidines as crf receptor antagonists |
| EP1701962A4 (en) | 2003-12-23 | 2008-03-05 | Activbiotics Inc | RIFAMYCIN ANALOGS AND USES THEREOF |
| RU2402553C2 (ru) * | 2005-02-11 | 2010-10-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2 |
| WO2008036579A1 (en) * | 2006-09-20 | 2008-03-27 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| US20110230464A1 (en) | 2007-10-26 | 2011-09-22 | Paul Goldsmith | Purine derivatives useful as p13 kinase inhibitors |
| JP2011513273A (ja) | 2008-02-26 | 2011-04-28 | ノバルティス アーゲー | Ｃｘｃｒ２の阻害剤としての複素環系化合物 |
| AU2009251291B2 (en) * | 2008-05-30 | 2013-05-02 | F. Hoffmann-La Roche Ag | Purine PI3K inhibitor compounds and methods of use |
| CA2742550A1 (en) * | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| EP2419429B1 (en) * | 2009-04-16 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines as inhibitors of protein kinases |
| CA2761445A1 (en) * | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| GB0912745D0 (en) | 2009-07-22 | 2009-08-26 | Wolfson Microelectronics Plc | Improvements relating to DC-DC converters |
| RU2012139182A (ru) | 2010-02-22 | 2014-03-27 | Ф. Хоффманн-Ля Рош Аг | ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RU2572624C2 (ru) | 2010-03-04 | 2016-01-20 | Мерк Шарп Энд Домэ Корп. | Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств |
| US9096605B2 (en) * | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
-
2015
- 2015-04-02 PL PL411864A patent/PL236355B1/pl unknown
-
2016
- 2016-03-30 CN CN201680017259.4A patent/CN107743489B/zh active Active
- 2016-03-30 ES ES16714019T patent/ES2765642T3/es active Active
- 2016-03-30 JP JP2017551627A patent/JP6665201B2/ja active Active
- 2016-03-30 HU HUE16714019A patent/HUE047822T2/hu unknown
- 2016-03-30 WO PCT/IB2016/051792 patent/WO2016157091A1/en active Application Filing
- 2016-03-30 CA CA2978828A patent/CA2978828A1/en active Pending
- 2016-03-30 US US15/562,537 patent/US10138247B2/en active Active
- 2016-03-30 EA EA201792087A patent/EA032826B1/ru not_active IP Right Cessation
- 2016-03-30 SI SI201630560T patent/SI3277687T1/sl unknown
- 2016-03-30 DK DK16714019.3T patent/DK3277687T3/da active
- 2016-03-30 PL PL16714019T patent/PL3277687T3/pl unknown
- 2016-03-30 KR KR1020177031214A patent/KR102559190B1/ko active IP Right Grant
- 2016-03-30 AU AU2016241568A patent/AU2016241568B2/en active Active
- 2016-03-30 EP EP16714019.3A patent/EP3277687B1/en active Active
- 2016-03-30 MX MX2017011423A patent/MX2017011423A/es active IP Right Grant
- 2016-03-30 PT PT167140193T patent/PT3277687T/pt unknown
- 2016-03-30 BR BR112017020131-3A patent/BR112017020131B1/pt active IP Right Grant
-
2019
- 2019-12-06 HR HRP20192195TT patent/HRP20192195T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3277687T3 (da) | 2019-12-16 |
| US10138247B2 (en) | 2018-11-27 |
| SI3277687T1 (sl) | 2020-02-28 |
| CN107743489A (zh) | 2018-02-27 |
| EP3277687A1 (en) | 2018-02-07 |
| US20180111939A1 (en) | 2018-04-26 |
| ES2765642T3 (es) | 2020-06-10 |
| BR112017020131B1 (pt) | 2023-02-28 |
| EA201792087A1 (ru) | 2018-03-30 |
| PL236355B1 (pl) | 2021-01-11 |
| PL3277687T3 (pl) | 2020-09-21 |
| JP6665201B2 (ja) | 2020-03-13 |
| KR20170132275A (ko) | 2017-12-01 |
| EP3277687B1 (en) | 2019-10-30 |
| AU2016241568A1 (en) | 2017-10-19 |
| BR112017020131A2 (pt) | 2018-05-29 |
| JP2018510192A (ja) | 2018-04-12 |
| PL411864A1 (pl) | 2016-10-10 |
| WO2016157091A1 (en) | 2016-10-06 |
| CN107743489B (zh) | 2021-05-04 |
| MX2017011423A (es) | 2018-05-17 |
| AU2016241568B2 (en) | 2019-09-26 |
| PT3277687T (pt) | 2020-01-10 |
| KR102559190B1 (ko) | 2023-07-25 |
| CA2978828A1 (en) | 2016-10-06 |
| EA032826B1 (ru) | 2019-07-31 |
| HRP20192195T1 (hr) | 2020-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268737A (en) | Processes for the preparation of benzodiapine derivatives | |
| EP3618829C0 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-ASSOCIATED DISORDERS | |
| HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| PH12015502780B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| PL3634417T3 (pl) | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| PL3473263T3 (pl) | Preparaty łączone do leczenia raka | |
| EP3373931A4 (en) | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | |
| HK1254651A1 (zh) | 吡唑並[1，5-a]嘧啶-3-甲酰胺的環醚衍生物 | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| PL3277687T3 (pl) | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| TH1501007495A (th) | อนุพันธ์ไพร์โรโล [3,2-d] ไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ |